Coherus Biosciences (NASDAQ:CHRS) Raised to “C-” at TheStreet

Share on StockTwits

Coherus Biosciences (NASDAQ:CHRS) was upgraded by TheStreet from a “d-” rating to a “c-” rating in a note issued to investors on Thursday, TheStreetRatingsTable reports.

A number of other equities analysts also recently issued reports on CHRS. Zacks Investment Research raised shares of Coherus Biosciences from a “hold” rating to a “buy” rating and set a $18.00 price objective on the stock in a report on Thursday. Barclays set a $31.00 price objective on shares of Coherus Biosciences and gave the stock a “buy” rating in a report on Monday, August 12th. Citigroup boosted their price target on shares of Coherus Biosciences from $27.00 to $31.00 and gave the stock a “buy” rating in a report on Thursday. BidaskClub downgraded shares of Coherus Biosciences from a “hold” rating to a “sell” rating in a report on Wednesday, October 16th. Finally, Mizuho set a $43.00 price target on shares of Coherus Biosciences and gave the stock a “buy” rating in a report on Sunday, September 29th. Two analysts have rated the stock with a sell rating and eight have assigned a buy rating to the stock. The stock has an average rating of “Buy” and a consensus price target of $30.38.

Coherus Biosciences stock traded up $0.06 during mid-day trading on Thursday, hitting $19.06. 1,353,200 shares of the stock were exchanged, compared to its average volume of 992,812. The stock has a market capitalization of $1.14 billion, a price-to-earnings ratio of -5.92 and a beta of 2.90. The firm’s fifty day simple moving average is $19.20 and its two-hundred day simple moving average is $19.18. Coherus Biosciences has a 12 month low of $8.32 and a 12 month high of $23.91.

Coherus Biosciences (NASDAQ:CHRS) last posted its quarterly earnings data on Wednesday, November 6th. The biotechnology company reported $0.63 earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of $0.36 by $0.27. The firm had revenue of $111.68 million for the quarter, compared to analysts’ expectations of $93.58 million. On average, analysts forecast that Coherus Biosciences will post 0.89 earnings per share for the current year.

In related news, CFO Jean-Frederic Viret sold 6,318 shares of the business’s stock in a transaction dated Wednesday, August 21st. The stock was sold at an average price of $21.71, for a total value of $137,163.78. Following the sale, the chief financial officer now directly owns 14,831 shares in the company, valued at approximately $321,981.01. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. Also, COO Vincent R. Anicetti sold 2,500 shares of the business’s stock in a transaction dated Wednesday, August 14th. The shares were sold at an average price of $19.00, for a total value of $47,500.00. The disclosure for this sale can be found here. Insiders sold a total of 25,264 shares of company stock worth $504,967 over the last three months. 18.20% of the stock is owned by insiders.

A number of institutional investors have recently made changes to their positions in the stock. BlackRock Inc. raised its stake in Coherus Biosciences by 10.6% in the 2nd quarter. BlackRock Inc. now owns 5,037,431 shares of the biotechnology company’s stock valued at $111,327,000 after acquiring an additional 483,541 shares during the period. Vanguard Group Inc. raised its stake in Coherus Biosciences by 3.0% in the 2nd quarter. Vanguard Group Inc. now owns 2,958,583 shares of the biotechnology company’s stock valued at $65,384,000 after acquiring an additional 87,091 shares during the period. Rock Springs Capital Management LP raised its stake in Coherus Biosciences by 180.6% in the 2nd quarter. Rock Springs Capital Management LP now owns 1,880,000 shares of the biotechnology company’s stock valued at $41,548,000 after acquiring an additional 1,210,000 shares during the period. Nuveen Asset Management LLC bought a new stake in Coherus Biosciences in the 2nd quarter valued at about $25,695,000. Finally, C WorldWide Group Holding A S raised its stake in Coherus Biosciences by 19.2% in the 3rd quarter. C WorldWide Group Holding A S now owns 808,464 shares of the biotechnology company’s stock valued at $16,379,000 after acquiring an additional 130,000 shares during the period. Institutional investors and hedge funds own 96.37% of the company’s stock.

Coherus Biosciences Company Profile

Coherus BioSciences, Inc, a commercial-stage biotherapeutics company, focuses on the biosimilar market worldwide. It markets UDENYCA, a long-acting granulocyte-colony stimulating factor, which stimulates production of granulocytes in order to promote the body's ability to fight infections. The company sells UDENYCA in the United States.

Read More: Why investors pay attention to retained earnings

Analyst Recommendations for Coherus Biosciences (NASDAQ:CHRS)

Receive News & Ratings for Coherus Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Coherus Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.



Latest News

Brokers Set Expectations for IAA’s FY2019 Earnings
Brokers Set Expectations for IAA’s FY2019 Earnings
FY2019 EPS Estimates for Osmotica Pharmaceuticals PLC Raised by Analyst
FY2019 EPS Estimates for Osmotica Pharmaceuticals PLC Raised by Analyst
Mackie Analysts Give Dolly Varden Silver  a C$1.00 Price Target
Mackie Analysts Give Dolly Varden Silver a C$1.00 Price Target
Deutsche Bank Analysts Give Vivendi  a €37.00 Price Target
Deutsche Bank Analysts Give Vivendi a €37.00 Price Target
Airbus  PT Set at €144.00 by Credit Suisse Group
Airbus PT Set at €144.00 by Credit Suisse Group
Insider Buying: Diverse Income Trust PLC  Insider Buys 27,733 Shares of Stock
Insider Buying: Diverse Income Trust PLC Insider Buys 27,733 Shares of Stock


 
© 2006-2019 Zolmax.